Background

Corona Remedies IPO: Blockbuster Listing, Strong Demand, Valuation Check

Author Image

Team Sahi

1 month ago•5 min read

Corona Remedies Ltd, a pharmaceutical formulations company, made a strong stock market debut on Monday, 15 December 2025, listing at ₹1,470 per share; a premium of around 40% over its issue price.The IPO is set to take place on both the NSE & BSE stock markets. The ₹655.37 crore IPO, which is entirely an Offer for Sale, is open for subscription from 8th to 10th December 2025. The stock offered is set within a price band of ₹1,008 to ₹1,062, and the grey market Premium is still consistent at 28% to 29%, which indicates that there are potential listing gains for the subscribers.

Subscription Snapshot

Investor Category Times Subscribed (Final)
Qualified Institutional Buyers (QIBs) ~293.80×
Non-Institutional Investors (NIIs) ~220.18×
Retail Individual Investors (RIIs) ~30.39×
Overall Subscription ~144.54×

Subscription numbers indicate an incredible spurt on Day 3, particularly in the institutional-tier slots, which reflects robust demand. Allocation has been locked in on 11th December 2025, and share credits/refunds are being processed. On the other hand, the GMP has been relatively strong, ranging from ₹290 to ₹305, indicating that people believe there is potential for listing, although this will be subject to market conditions on 15th December.

About the Company

Corona Remedies Ltd is a differentiated leader in the pharmaceutical industry in India, with a focus on the development of franchises in the following therapeutic areas: Women’s healthcare, Cardio-diabetes, Pain management, Urology. It is a significant player with a strong product franchise, which comprises a total of 71+ brands with 27 “key engine brands” that contribute to over 70% of the domestic business, with a number of them occupying a #1 position in their respective markets. The strengths of this business are a robust distribution network, with thousands of medical representatives in 22 states of India, as well as a strong association with a supporting business (La Chandra Pharmalab), which is EU-GMP and WHO-GMP certified for hormone API production.

Corona Remedies Financial Snapshot

The Corona Remedies IPO is an entirely "Offer for Sale" issue, which means that the company itself won't raise any money from this issue. In this IPO, existing shareholders, including promoters and private individuals, sold 61.71 lakh shares of the company through the IPO.

Financial Metric FY23 FY24 FY25
Revenue* 884.05† 1,014.47† 1,196.41†
PAT* 84.93† 90.50† 149.43†

Competitor Analysis

Corona Remedies has to compete with established pharma formulation giants such as Cipla Ltd, Dr. Reddy’s Laboratories Ltd, and Lupin Ltd, who have a diverse product range with a strong presence globally. For a domestic-market-focused, branded formulation company such as Corona Remedies, these competitors make apt approximates in terms of benchmarks for performance:

Company (Listed Peer) Revenue (₹ crore) Net Profit (₹ crore) Market Capitalisation*
Sun Pharmaceutical Industries ~49,000 ~8,300 ₹4.8 lakh crore
Cipla Ltd ~26,000 ~4,200 ₹1.2 lakh crore
Dr. Reddy’s Laboratories ~28,000 ~6,500 ₹1.1 lakh crore
Lupin Ltd ~20,000 ~3,000 ₹1.0 lakh crore

Corona Remedies IPO Review

The Corona Remedies IPO is a highly attractive branded pharma story with a strong domestic growth base and an optimizing profitability position, as per analysts. The overall growth trajectory, with increasing profitability, tight brand focus on high-growth segments, makes it stand apart from most other listed mid-cap pharma stocks. However, dependence on a strong brand franchise and familiarity with the domestic market might become a challenge, especially with increased competitive or pricing pressure. The forward multiples (about 43 times Forward '25 earnings), combined with a high GMP, are a positive indication, but the sustainability of valuations, especially in the aftermath of listing, is paramount.

All topics

IPOProduct UpdatesMarket UpdatesOptions 101Option Strategy 101Stocks 101ChartsTrading 101

Over 1 Million Downloads

Built by
experienced traders & technologists

Backed by
the investors of world leading companies

acccl.pngelevation.png
Footer Graphic
Aaritya Broking Private Limited
3rd Floor, Brigade Metropolis,
Summit B, Whitefield,
Bangalore, Karnataka – 560048



Aaritya Broking Private Limited
CIN: U66120KA2023PTC180274
Aaritya Technologies Private Limited
CIN: U62091KA2023PTC175489

Company

Products

Platforms

Useful Links

Risk disclosures on derivatives -

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.

Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost. ATTENTION – A note from the Regulators for Investors

  • Stock brokers can accept securities as margin from clients only by way of pledge in the depository system, with effect from Sept 1, 2020.
  • Update your mobile number and email ID with your stock broker/depository participant and receive OTP directly from depository on your email ID and/or mobile number to create pledges.
  • Pay 20% upfront margin of the transaction value to trade in the Cash market segment.
  • Investors may please refer to the Exchanges’ (NSE and BSE) Frequently Asked Questions (FAQs), issued vide circular reference NSE/INSP/45191 and 20200731-7 dated July 31, 2020; NSE/INSP/45534 and 20200831-45 dated Aug 31, 2020; notice no. 20200731-7 dated July 31, 2020 and 20200831-45 dated Aug 31, 2020; and other guidelines issued from time to time in this regard.
  • Check your Securities/MF/Bonds in the consolidated account statement issued by NSDL/CDSL every month.

SEBI Stock Broker Registration No: INZ000317632 | Depository Participant (CDSL) ID: IN-DP-780-2024 | Registration Number of the Research Analyst: INH000022172
Exchange Membership No: NSE: 90375 | BSE: 6867

Registered Office: Aaritya Broking Private Limited, 3rd Floor, Brigade Metropolis, Summit B, Whitefield, Bangalore, Karnataka – 560048, Contact Number - 080-47092788.

In case of grievances for any of the services rendered by Aaritya Broking Private Limited, please write to grievance@aaritya.com (for NSE and BSE) or dpgrievance@aaritya.com (for CDSL Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Vaibhav Satalkar and Contact Number: 080-470-92788

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI-registered intermediary (broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to an IPO. Just write the bank account number and sign the application form to authorise your bank to make a payment in case of allotment. No worries for a refund as the money remains in the investor's account.

"Prevent Unauthorised Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day - Issued in the interest of investors."

Important Links: SEBI | BSE | NSE | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | UCC Advisory – KYC Compliance | e-Voting for Shareholders | KYC document in Vernacular Language – NSE | BSE | Account Opening Procedure | Filing a complaint | SCORES – Easy & quick | Research Disclaimer

Important Information: Policies and Procedures | Terms & Conditions | Anti Money Laundering Policy | RMS Policy | Filing complaints on SCORES - Easy & quick | KYC (Trading + DP account) | Complaints Disclosure | Bank A/c Disclosure | Key Managerial Personnel | Investor Risk Reduction Access (IRRA) | Saarthi 2.0 Mobile | Surveillance Policy | GTT and GTC order facility | Most Important Terms and Conditions (MITC) 

All Rights Reserved | © Copyright 2026